Oral Session 3-15D AML: Novel Therapy

[OS3-15D-3] Immunological analysis of a peptide vaccine, OCV-501 in elderly patients with acute myeloid leukemia

Naoki Takezako¹, Masaki Yamaguchi², Toru Kiguchi³, Shuichi Miyawaki⁴, Yuji Heike⁵, Koichi Masui⁶, Nami Tagami⁷, Tomoki Naoe⁸ (1.Dept. of Hematology, NHO Disaster Medical Center, Tokyo, Japan, 2.Dept. of Hematology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan, 3.Dept. of Hematology, Chugoku Central Hospital, Fukuyama, Japan, 4.Dept. of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 5.Immunotherapy and Cell Therapy, St. Luke's International Hospital, Tokyo, Japan, 6.Clinical Management, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 7.Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 8.National Hospital Organization Nagoya Medical Center, Nagoya, Japan)